26 results
8-K
EX-99.2
bm2p673nzcbnakfpa27
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.2
pad1fke41kwhm d5
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
DEFA14A
kxmgb
11 Apr 22
Additional proxy soliciting materials
4:36pm
10-K
ng5k7e71 be
25 Mar 21
Annual report
12:00am
424B4
06q27
21 Jan 21
Prospectus supplement with pricing info
12:00am
8-K
EX-99.1
f537m
11 Jan 21
Departure of Directors or Certain Officers
6:03am
DRS
mqibhvo
6 Jan 21
Draft registration statement
12:00am